Leukemia Market

The global leukemia market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.

Leukemia is a type of cancer that affects the blood and bone marrow. It originates in the bone marrow and results in the abnormality in leucocytes or white blood cells. White blood cells help body fight infection, and they are formed in the bone marrow. In leukemia, the bone marrow starts producing abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. The major types of leukemias include acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Prevalence of leukemia is quite high globally. According to the American Cancer Society (ACS), there will be around 62,000 estimated cases of Leukemia in 2019 in U.S. Leukemia begins in a cell in the bone marrow and changes the cell to become a type of leukemia cell. After the leukemic change, the leukemia cells may grow and survive better than normal cells. With time, the leukemia cells crowd out or suppress the development of normal cells. The rate of replacement of normal blood and marrow cells and at which leukemia progress are different with each type of leukemia. Leukemia occurs most often in adults older over the age of 55, but it is also the most common cancer in children younger than 15.


Global Leukemia Market Dynamics

The market is driven by a rise in prevalence population, robust pipeline, rise in healthcare expenditure, and technological advancements. 

Childhood leukemia is the most common type of cancer in children and teens. The incidence rate of Leukemia is highest in children, among other cancers.

High costs associated with drug development and adverse side-effects related to chemotherapeutic options are going to restrain the market in the forecast period.

Global Leukemia Market Segmentation Analysis

The global leukemia market can be segmented by disease type as Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Chronic Myeloid Leukemia and by treatment type as Medication, Surgery, Chemotherapy, Biological Therapy, Immunotherapy, Radiation Therapy, Targeted Therapy, and Stem Cell Transplantation.

Acute Lymphocytic Leukemia is the most common type of Leukemia among children. According to ACS, around 3 out of 4, childhood leukemias are Acute Lymphocytic Leukemia. This leukemia starts in early forms of white blood cells called lymphocytes. Over the period of forecast incidence cases of Acute Lymphocytic Leukemia are expected to grow, leading to growth in their therapeutics market. This cancer usually gets worse quickly if it is not treated. In a child with this type of cancer, too many stem cells become lymphoblasts, B lymphocytes, or T lymphocytes. The cells do not work like normal lymphocytes and are not able to fight infection very well. These cells are cancer cells. Also, as the number of leukemia cells increases in the blood and bone marrow, there is less room for healthy white blood cells, red blood cells, and platelets. This leads to infection, anemia, and easy bleeding.

Chemotherapy is the use of anti-cancer drugs that are injected into the vein, under the skin, or into the cerebrospinal fluid. When given into the cerebrospinal fluid, these drugs enter the bloodstream and reach all areas of the body, making this treatment useful for leukemia that spread throughout the body. Chemotherapy is the main treatment for most people with leukemia. Chemotherapy uses potent drugs or chemicals, often in combinations or intervals, to kill or damage cancer cells in the body. 

Global Leukemia Market Geographical Share

Geographically, the global leukemia market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to dominate the market in the forecast period followed by Europe. High disease awareness, favorable reimbursement policies, high healthcare access, advanced healthcare infrastructure, high disease prevalence, and government initiatives are critical factors for the substantial growth of the market in North America regions.

The Asia Pacific is anticipated to have the highest growth rate in the forecast period due to the development of the healthcare infrastructure, especially contributed by developing countries like China and India. Rising investments for R&D activities are projected to encourage the growth of the leukemia market in the region. Also, increasing healthcare expenditures, rising prevalence of leukemia are also expected to fuel the market growth in the forecast period. According to the World Health Organization (WHO) database, Australia and New Zealand have the highest regional leukemia rate in the world with around 11.3 per 100,000 population for 2012.


Global Leukemia Market Competitive Trends

Some of the major key players in the market are AbbVie, Novartis, Pfizer, Bristol-Myers Squibb Company, Genzyme, Celgene, GlaxoSmithKline, Cephalon, Eisai and Teva Pharmaceuticals.

In January 2019, AbbVie received FDA approval for IMBRUVICA (ibrutinib) Plus Obinutuzumab (GAZYVA®) - first chemotherapy-free, anti-cd20 combination regimen approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) in previously untreated patients.

In February 2019, Bristol-Myers Squibb’s Sprycel (dasatinib) tablets got approval in combination with chemotherapy in certain pediatric patients with philadelphia chromosome-positive acute lymphoblastic leukemia.

In January 2019, AbbVie, and Tizona Therapeutics announce strategic collaboration to develop first-in-class immunotherapy for cancer targeting CD39, including TTX-030.

In December 2018, Novartis announced longer-term analyses from pivotal Kymriah trials that showed durable responses are maintained in patients with advanced blood cancers.

In August 2018, Novartis received European Commission approval of CAR-T cell therapy, Kymriah (tisagenlecleucel) for B-cell acute lymphoblastic leukemia.

In June 2018, Novartis received positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe.

In November 2018, Pfizer Inc. received FDA approvel for DAURISMO (glasdegib), a once-daily oral medicine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy.


Why purchase the report?

  • Visualize the composition of the leukemia market across each indication, in terms of type and by type highlighting the key commercial assets and players.
  • Identify commercial opportunities in leukemia by analyzing trends and co-development deals.
  • Excel data sheets with thousands of data points of leukemia market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players.


Target Audience:

  • Medical device companies
  • Hospitals and clinics
  • Research and consulting firms
  • Healthcare associations/institutes
  • Venture capitalists
  • Government agncies

Global Leukemia Market

1. Leukemia Market – Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2. Leukemia Market – Market Definition and Overview

3. Leukemia Market – Executive Summary

3.1. Market Snippet by Disease Type

3.2. Market Snippet by Treatment Type

3.3. Market Snippet by Region

3.4. DataM CLO Scenario

4. Leukemia Market – Market Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Rise in prevalence population

4.1.1.2. Drug launches and robust pipeline

4.1.1.3. Rise in healthcare expenditure

4.1.2. Restraints

4.1.2.1. High costs associated with drug development

4.1.2.2. Adverse side-effects

4.1.3. Opportunity

4.1.4. Impact Analysis

5. Leukemia Market – Industry Analysis 

5.1. Porter's Five Forces Analysis

5.2. Regulatory Analysis

5.3. Epidemiology

5.4. Pipeline Insights

5.5. Key Companies to Watch

6. Leukemia Market – By Disease Type

6.1. Introduction

6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

6.3. Market Attractiveness Index, By Disease Type

6.4. Acute Lymphocytic Leukemia

6.4.1. Introduction

6.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

6.5. Chronic Lymphocytic Leukemia

6.6. Acute Myeloid Leukemia

6.7. Chronic Myeloid Leukemia

7. Leukemia Market – By Treatment Type

7.1. Introduction

7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

7.3. Market Attractiveness Index, By Treatment Type

7.4. Surgery 

7.4.1. Introduction

7.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

7.5. Chemotherapy

7.6. Immunotherapy

7.7. Radiation Therapy

7.8. Targeted Therapy

7.9. Stem Cell Transplantation

8. Leukemia Market – By Region

8.1. Introduction 

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

8.3. Market Attractiveness Index, By Region

8.4. North America

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.4.5.1. U.S.

8.4.5.2. Canada

8.4.5.3. Mexico

8.5. Europe

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.5.5.1. Germany

8.5.5.2. U.K.

8.5.5.3. France

8.5.5.4. Italy

8.5.5.5. Spain

8.5.5.6. Rest of Europe

8.6. South America

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

8.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.6.5.1. Brazil

8.6.5.2. Argentina

8.6.5.3. Rest of South America

8.7. Asia-Pacific

8.7.1. Introduction

8.7.2. Key Region-Specific Dynamics

8.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

8.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.7.5.1. China

8.7.5.2. India

8.7.5.3. Japan

8.7.5.4. Australia

8.7.5.5. Rest of Asia Pacific

8.8. Middle East and Africa

8.8.1. Introduction

8.8.2. Key Region-Specific Dynamics

8.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

9. Leukemia Market – Competitive Landscape

9.1. Competitive Scenario

9.2. Competitor Leukemia Strategy Analysis

9.3. Comparative Product Portfolio Analysis

9.4. Market Positioning/Share Analysis

9.5. Mergers and Acquisitions Analysis

10. Leukemia Market – Company Profiles

10.1. AbbVie, Inc. *

10.1.1. Company Overview

10.1.2. Product Portfolio and Description

10.1.3. Key Highlights

10.1.4. Financial Overview

10.2. Novartis

10.3. Pfizer

10.4. Bristol-Myers Squibb Company

10.5. Genzyme

10.6. Celgene

10.7. GlaxoSmithKline

10.8. Cephalon

10.9. Eisai

10.10. Teva Pharmaceuticals

10.11. Company XX

10.12. Company XX

11. Leukemia Market – Premium Insights

12. Leukemia Market – DataM

12.1. Appendix

12.2. About Us and Services

12.3. Contact Us

List of Tables

Table 1 Global Leukemia Market Value, By Disease Type, 2018,2022 & 2026 ($ Million)

Table 2 Global Leukemia Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 3 Global Leukemia Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 4 Global Leukemia Market Value, By Disease Type, 2018,2022 & 2026 ($ Million)

Table 5 Global Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 6 Global Leukemia Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 7 Global Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 8 Global Leukemia Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 9 Global Leukemia Market Value, By Region, 2017-2026 ($ Million)

Table 10 North America Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 11 North America Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 12 North America Leukemia Market Value, By Country, 2017-2026 ($ Million)

Table 13 South America Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 14 South America Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 15 South America Leukemia Market Value, By Country, 2017-2026 ($ Million)

Table 16 Europe Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 17 Europe Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 18 Europe Leukemia Market Value, By Country, 2017-2026 ($ Million)

Table 19 Asia-Pacific Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 20 Asia-Pacific Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 21 Asia-Pacific Leukemia Market Value, By Country, 2017-2026 ($ Million)

Table 22 Middle East & Africa Leukemia Market Value, By Disease Type, 2017-2026 ($ Million)

Table 23 Middle East & Africa Leukemia Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 24 AbbVie, Inc.: Overview

Table 25 AbbVie, Inc.: Product Portfolio

Table 26 AbbVie, Inc.: Key Developments

Table 27 Novartis: Overview

Table 28 Novartis: Product Portfolio

Table 29 Novartis: Key Developments

Table 30 Pfizer: Overview

Table 31 Pfizer: Product Portfolio

Table 32 Pfizer: Key Developments

Table 33 Bristol-Myers Squibb Company: Overview

Table 34 Bristol-Myers Squibb Company: Product Portfolio

Table 35 Bristol-Myers Squibb Company: Key Developments

Table 36 Genzyme: Overview

Table 37 Genzyme: Product Portfolio

Table 38 Genzyme: Key Developments

Table 39 Celgene: Overview

Table 40 Celgene: Product Portfolio

Table 41 Celgene: Key Developments

Table 42 GlaxoSmithKline: Overview

Table 43 GlaxoSmithKline: Product Portfolio

Table 44 GlaxoSmithKline: Key Developments

Table 45 Cephalon: Overview

Table 46 Cephalon: Product Portfolio

Table 47 Cephalon: Key Developments

Table 48 Eisai: Overview

Table 49 Eisai: Product Portfolio

Table 50 Eisai: Key Developments

Table 51 Teva Pharmaceuticals: Overview

Table 52 Teva Pharmaceuticals: Product Portfolio

Table 53 Teva Pharmaceuticals: Key Developments


 List of Figures

Figure 1 Global Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 2 Global Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 3 Global Leukemia Market Share, By Region, 2018 & 2026 (%)

Figure 4 Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 5 Global Leukemia Market Y-o-Y Growth, By Disease Type, 2018-2026 (%)

Figure 6 Acute Lymphocytic Leukemia: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 7 Chronic Lymphocytic Leukemia: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 8 Acute Myeloid Leukemia: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 9 Chronic Myeloid Leukemia: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 10 Global Leukemia Market Y-o-Y Growth, By Treatment Type, 2018-2026 (%)

Figure 11 Medication: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 12 Surgery: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 13 Chemotherapy: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 14 Biological Therapy: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 15 Immunotherapy: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 16 Radiation Therapy: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 17 Targeted Therapy: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 18 Stem Cell Transplantation: Global Leukemia Market Value, 2017-2026 ($ Million)

Figure 19 Global Leukemia Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 20 North America Leukemia Market Value, 2017-2026 ($ Million)

Figure 21 North America Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 22 North America Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 23 North America Leukemia Market Share, By Country, 2018 & 2026 (%)

Figure 24 South America Leukemia Market Value, 2017-2026 ($ Million)

Figure 25 South America Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 26 South America Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 27 South America Leukemia Market Share, By Country, 2018 & 2026 (%)

Figure 28 Europe Leukemia Market Value, 2017-2026 ($ Million)

Figure 29 Europe Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 30 Europe Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 31 Europe Leukemia Market Share, By Country, 2018 & 2026 (%)

Figure 32 Asia-Pacific Leukemia Market Value, 2017-2026 ($ Million)

Figure 33 Asia-Pacific Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 34 Asia-Pacific Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 35 Asia-Pacific Leukemia Market Share, By Country, 2018 & 2026 (%)

Figure 36 Middle East & Africa Leukemia Market Value, 2017-2026 ($ Million)

Figure 37 Middle East & Africa Leukemia Market Share, By Disease Type, 2018 & 2026 (%)

Figure 38 Middle East & Africa Leukemia Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 39 AbbVie, Inc.: Financials

Figure 40 Novartis: Financials

Figure 41 Pfizer: Financials

Figure 42 Bristol-Myers Squibb Company: Financials

Figure 43 Genzyme: Financials

Figure 44 Celgene: Financials

Figure 45 GlaxoSmithKline: Financials

Figure 46 Cephalon: Financials

Figure 47 Eisai: Financials

Figure 48 Teva Pharmaceuticals: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report